LipoScience Unveils Research Supporting NMR Diabetes Risk Test At The 2013 American Diabetes Association Scientific Sessions
Data Presentation Demonstrates Value of Test in Stratifying a Patient’s Risk of Developing Type 2 Diabetes
RALEIGH, N.C., June 22, 2013 /PRNewswire/ – LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced the presentation of data from a clinical study at the 73(rd) Scientific Sessions of the American Diabetes Association (ADA) from June 21-25 in Chicago, Ill.
During a moderated poster presentation on June 22 at 12:30 p.m. CT, researchers from LipoScience presented data for the first time demonstrating the performance of the company’s research version of an NMR-based diabetes risk index to stratify a patient’s risk of developing type 2 diabetes, so that high-risk patients may receive the benefit of more timely and focused clinical interventions intended to slow or prevent the progression to diabetes.
The NMR diabetes risk index is a lab-based multivariate assay that uses proprietary NMR-derived biomarkers of insulin resistance and inflammation to determine a patient’s risk of developing type 2 diabetes. The test thus provides researchers and clinicians with the means to help distinguish those individuals with a higher versus lower likelihood of progressing to type 2 diabetes at any given level of fasting plasma glucose (FPG) or glycosylated hemoglobin (HbA1c).
“In current medical practice, elevated FPG or HbA1c levels are used to identify patients with ‘prediabetes’. Our results suggest that a much more refined assessment of diabetes risk beyond that provided by glucose measurements can be made by taking account of the underlying metabolic defects that lead to type 2 diabetes,” commented James Otvos, PhD, Chief Scientific Officer of LipoScience. “NMR spectral ‘signatures’ exist for several of these metabolic defects, which we have combined into a simple-to-use diabetes risk index. Our hope is that this new tool will enable clinicians to more readily identify those patients with the highest risk who stand to benefit the most from targeted risk-reduction treatment strategies.”
Development of the NMR diabetes risk index
Dr. James Otvos of LipoScience described the development of the NMR diabetes risk test that uses only information derived from an automated NMR measurement of a fasting plasma sample. The investigators used NMR data collected at baseline from a large multi-ethnic study population to develop the diabetes risk index, with a higher score indicating higher risk. Of the 4,985 non-diabetic participants in the study, 411 developed type 2 diabetes during six years of follow-up. Among the subjects with intermediate fasting glucose levels of 90-110 mg/dL, for whom the most uncertainty exists about diabetes risk, a high versus low value of the NMR diabetes risk index translated into greater than 10-fold differences in the rates of conversion to diabetes.
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company’s first proprietary diagnostic test, the NMR LipoProfile(®) test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 9 million NMR LipoProfile tests have been ordered. LipoScience’s automated clinical analyzer, Vantera(®), has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.
LipoScience is driving NMR diagnostics toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the Company’s plans, objectives, expectations (financial and otherwise) or intentions. These forward-looking statements include statements about the Company’s plans for potential future diagnostic tests. Actual results may differ significantly from those projected or suggested in any forward-looking statements. Further information on potential factors and other risks that could affect the Company’s business and operating results is included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and other filings the Company makes with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations page of the Company’s website at http://investor.liposcience.com/. The statements made herein are based on information available to LipoScience as of the date of this press release, and the Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
SOURCE LipoScience, Inc.